Recent clinical trials showed that IFN-α therapy significantly reduced viral shedding and levels of inflammatory biomarkers, whereas IFN-β therapy improved virologic clearance; both therapies led to improved recovery in patients with COVID-19 (68, 69). The gene discussed is IFNA1; the disease is COVID-19.